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Abstract
It has been reported that schistosomiasis-associated PAH (Sch-PAH) has a more benign clinical course compared with
idiopathic PAH (IPAH). We therefore hypothesized that Sch-PAH subjects would present with less impaired cardiopulmonary
and metabolic responses to exercise than IPAH patients, even with similar resting pulmonary hemodynamic abnormalities.
The aim of this study was to contrast physiologic responses to incremental exercise on cycle ergometer between subjects
with Sch-PAH and IPAH. We performed incremental cardiopulmonary exercise tests (CPET) in subjects newly diagnosed with
IPAH (n = 9) and Sch-PAH (n = 8), within 1 month of the hemodynamic study and before the initiation of specific therapy for
PAH. There were no significant between-group differences in cardiac index, pulmonary vascular resistance or mean
pulmonary artery pressure. However, mean peak oxygen uptake (VO2) was greater in Sch-PAH than IPAH patients
(75.5621.4 vs 54.1616.1% predicted, p = 0.016), as well as the ratio of increase in VO2 to work rate (8.261.0 vs 6.861.8 mL/
min/W, p= 0.03). Additionally, the slope of the ventilatory response as a function of CO2 output was lower in Sch-PAH
(40.363.9 vs 55.6619.8; p = 0.04), and the heart rate response for a given change in VO2 was also diminished in Sch-PAH
compared to IPAH (80.1620.6 vs 123.0639.2 beats/L/min; p = 0.02). In conclusion, Sch-PAH patients had less impaired
physiological responses to exercise than IPAH subjects with similar resting hemodynamic dysfunction. Our data suggest a
more preserved cardiopulmonary response to exercise in Sch-PAH which might be related to its better clinical course
compared to IPAH.
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Introduction
Schistosomiasis is potentially the most common cause of
pulmonary arterial hypertension (PAH) worldwide. [1,2] Although
80 years have passed since the first description of cardiopulmonary
involvement caused by schistosoma species, this association has not
been well studied. [3] Thus, little is known about the pathophys-
iology, natural history and therapeutic response of schistosomiasis-
associated PAH (Sch-PAH).
A recent study demonstrated that naı¨ve Sch-PAH patients had
similar survival rates compared to idiopathic PAH (IPAH) subjects
treated with vasodilators. In an additional analysis, the authors
suggested that Sch-PAH patients have a more benign clinical
course than those with IPAH. [4] The mechanisms related to this
finding were not described, but it might be related to a slower
progression of arteriopathy in Sch-PAH.
Clinicians evaluate functional impairment in PAH patients
using the New York Heart Association functional class assessment
(NYHA-FC), six-minute walking distance (6MWD) and/or car-
diopulmonary exercise testing (CPET). [5,6] However, only CPET
is able to properly identify the physiological mechanisms linked to
functional impairment, including ventilatory limitation, circulatory
dysfunction or impaired oxygen utilization in peripheral muscles.
[7,8] In fact, CPET has emerged as a surrogate method to
evaluate functional impairment in many diseases, and there is a
robust body of evidence addressing the diagnostic and prognostic
usefulness of CPET in PAH patients.[7–13] Moreover, several
abnormal CPET findings have been linked to PAH pathophys-
iology and disease severity. Compared to healthy subjects, patients
with PAH show a reduced aerobic capacity, a high slope of
minute-ventilation change as a function of CO2 production
[(DVE/DVCO2), a marker of ventilatory inefficiency], an abnor-
mally diminished end-tidal partial pressure of CO2 (PETCO2) at
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the anaerobic threshold and a steeper increase in heart rate as a
function of the metabolic demand (DHR/DVO2). These abnor-
malities have been ascribed to the inability of the right ventricle to
increase cardiac output through the pulmonary vascular bed,
inefficient gas exchange due to ventilation-perfusion mismatching,
and/or abnormalities in the control of ventilation. [7,8] In this
context, it is conceivable that patients with Sch-PAH would
present with less severe hemodynamic abnormalities during
incremental exercise compared with those with IPAH. To the
best of the authors’ knowledge, this assertion has not been
previously investigated. So, the aim of this study was to contrast
the physiological responses during CPET of Sch-PAH and IPAH
patients. We hypothesized that Sch-PAH subjects would have
better functional performance compared to IPAH patients as
indicated by higher maximal aerobic capacity and less impaired
ventilatory, cardiovascular and gas exchange responses to exercise.
Materials and Methods
Subjects
This was a cross-sectional study in which incremental CPET
was performed in subjects diagnosed with IPAH and Sch-PAH
between 2007 and 2010. The test was performed within 1 month
of the hemodynamic study and before the initiation of specific
therapy for PAH.
PAH was defined as a mean pulmonary artery pressure (mPAP)
$25 mmHg with a pulmonary capillary wedge pressure (PCWP)
#15 mmHg. [5,6] Patients were classified as having IPAH when a
routine investigation did not find any cause for PAH. Sch-PAH
was characterized by the presence of PAH associated with liver
ultrasonographic findings suggestive of hepatoesplenic schistoso-
miasis (periportal fibrosis and/or left lobe enlargement) and at
least one of the following: exposure to a region endemic for
schistosomiasis, previous treatment for schistosomiasis or the
presence of Schistosoma mansoni eggs in a stool examination or rectal
biopsy. [1,4].
Subjects were excluded from study if they had evidence of any
of the following: right-to-left intracardiac shunt, resting hypox-
emia, hospitalization in the last month, or an orthopedic limitation
to cycling. None of the patients had ever been admitted to a
physical rehabilitation program.
Measurements
At the baseline evaluation, we obtained a medical history that
included an NYHA-FC assessment, transthoracic echocardio-
gram, spirometry, single breath carbon monoxide diffusing
capacity (DLCO), resting arterial blood gases and 6MWD from
all patients. [14].
Hemodynamic Evaluation
A right-sided heart catheterization was performed using
standard techniques. Cardiac output (CO) was determined by
the Fick method, with arterial and venous line, and estimated VO2
(125x body surface area). [15–17] Acute vasodilator responsiveness
was evaluated using inhaled nitric oxide for 10 minutes, with a
positive response defined as a fall in the mPAP of 10 mmHg or
more (to a value #40 mmHg) without a decrease in CO. [5,6].
Cardiopulmonary Exercise Testing (CPET)
Patients performed a symptom-limited ramp-incremental
CPET on an electronically braked cycle ergometer (Corival 400,
Lode, The Netherlands) at 60 rpm. O2 uptake (VO2, L/min), CO2
output (VCO2, L/min), minute ventilation (VE, L/min), the
respiratory exchange ratio (RER, VCO2/VO2) and the end-tidal
partial pressures for CO2 (PETCO2, mmHg) and O2 (PETO2,
mmHg) were measured using a computer-based system, with
breath-by-breath analysis (CardiO2 System
TM, Medical Graphics,
St. Paul, MN) and were recorded as mean of 15 s. Heart rate (HR,
bpm) was recorded from the R-R distance in 12-lead ECG tracing
with on-line calculation of O2 pulse (VO2/HR, ml/beat) and also
sampled as mean of 15 s. The peak VO2 was compared to
Brazilian standards. [18].
The anaerobic threshold (AT) was identified using the modified
V-slope and the ventilatory method as previously described. The
DHR/DVO2, DVE/DVCO2 and the slope of VO2 as a function of
work rate (DVO2/DWR) during the incremental phase were
calculated from the start of increases in VO2 to the respiratory
compensation point, according to standard procedures. [7,19].
Cuff blood pressure and pulse oximetry were monitored and
recorded. At the end of the test, subjects were asked to rate their
‘‘dyspnea’’ and ‘‘leg fatigue’’ using the 0–10 Borg’s category-ratio
scale. [20].
Ethics Statement
The study protocol was approved by the Institutional Medical
Ethics Committee: Hospital Sa˜o Paulo – UNIFESP (nu
04878612.4.0000.5505) and written informed consent was ob-
tained from all subjects.
Statistical Analysis
Statistical analysis was performed using the SPSS 19 statistical
package (SPSS, Inc., Chicago, IL). All continuous variables had
normal distribution as stated by the Kolmogorov-Smirnov test.
Therefore, an unpaired t-test was used for the comparison of
resting hemodynamics and exercise responses. We used ANOVA
with Bonferroni correction for multiple comparisons. Pearson’s
product moment correlation or Spearman’s rank correlation was
used according to assess the level of correlation between variables.
A p value of less than 0.05 was considered statistically significant.
Results
Patient Population
In our cohort, there were 9 subjects with IPAH and 8 subjects
with Sch-PAH who met the study criteria and were able to enter
the study. At the baseline evaluation, the demographic character-
istics of the IPAH and Sch-PAH groups were similar (Table 1).
Most patients were in functional class II or III, and there were no
differences in 6MWD between the 2 groups. None of the patients
with Sch-PAH had anemia or abnormal liver function tests.
Resting Pulmonary Hemodynamics
Hemodynamic parameters are summarized in Table 2. There
were no significant differences in mean pulmonary pressure
(mPAP), pulmonary vascular resistance (PVR), or cardiac index
(CI) between groups. No patient displayed positive acute
vasodilator response to inhaled nitric oxide.
Physiological Responses to Exercise
All subjects exhibited diminished aerobic capacity, with the test
being interrupted by symptoms of breathlessness in 66% of IPAH
subjects and leg effort in 75% of Sch-PAH subjects. The
measurements of CPET variables in each group are presented in
Table 3 and the typical physiological responses of Sch-PAH and
IPAH patients to selected variables obtained during the CPET are
presented in Figure 1.
Compared with IPAH patients, Sch-PAH subjects had greater
peak VO2 and higher DVO2/DWR. Also, VO2 was higher in the
Contrasting Exercise Responses in Sch-PAH and IPAH
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Sch-PAH group at the AT. The DVE/DVCO2 was lower in Sch-
PAH patients than IPAH patients. Although VE/VCO2 and
PETCO2 at AT were smaller in Sch-PAH patients, these variables
did not reach statistical significance. There was a trend for
different PETCO2 behavior between the groups during exercise
(Figure 2).
Sch-PAH patients had a shallower heart rate response for a
given change in VO2 and, accordingly, a greater peak O2 pulse
compared to IPAH subjects (p,0.05). No difference in SpO2 at
rest and peak exercise was found between the groups. Mild
hypoxemia during the test was only noted in 3 patients, 2 of which
were from the Sch-PAH group.
Resting cardiac index was significantly correlated to peak VO2
only in IPAH subjects. Likewise, there was a correlation between
peak VO2 and resting CI with VO2-WR and VE-VCO2 slopes in
patients with IPAH, but not in subjects with Sch-PAH. In both
groups, there were correlations between resting CI and peak VO2,
with NYHA-FC, but not with 6MWT (Table 4; Table 5).
Discussion
To the best of our knowledge, this is the first study to
comparatively assess the physiological adjustments to progressive
exercise in subjects with Sch-PAH and IPAH. Although it is an
initial study with a small sample, our results indicated that Sch-
PAH patients exhibit less impaired exercise responses than IPAH
patients, even if they had similar resting pulmonary hemodynamic
abnormalities. These data might provide a mechanistic explana-
tion for the reported differences in disease progression.
There are potentially more than twice the number of people
with Sch-PAH than IPAH worldwide. [2,3] Even in non-endemic
regions, the prevalence of schistosomiasis is relevant, as demon-
strated in a recent report from the French National Center for
PAH that showed that schistosomiasis was present in 11% of
patients with PAH attributed to non-cirrhotic portal hypertension.
[21] Little is known about the pathophysiology of Sch-PAH, and it
was previously classified as PAH attributed to embolic phenomena
– schistosoma eggs from the portal-hepatic system. [22,23]
However, later studies showed that the histopathological features
of Sch-PAH were similar to IPAH, even with the absence of eggs
in the pulmonary arteries. It is possible that the presence of
schistosoma eggs in the portal veins could trigger an inflammatory
response or an imbalance in the vasoactive mediators in the
pulmonary arteries. [23].
Fernandes et al. [4] showed that Sch-PAH patients present with
less severe disease, exhibiting more preserved resting pulmonary
hemodynamics and a trend toward better functional status than
IPAH patients. They reported similar survival rates between naı¨ve
Sch-PAH subjects and IPAH subjects treated with vasodilators,
suggesting a more benign clinical course for Sch-PAH. The
baseline characteristics of our patients in both groups were similar
to those described by Fernandes et al. [4], and we did not find a
trend toward better NYHA-FC, 6MWD and resting hemody-
namics in Sch-PAH patients. We did, however, find striking
differences between groups during the evaluation of some of the
exercise responses obtained in the CPET, as described below.
Differences in Aerobic Capacity and Work Efficiency
In healthy subjects, the VO2 increases as a function of cardiac
output and O2 extraction, responding to muscle demand during
exercise. In PAH, this response could mainly be impaired due to
the failure of the right heart to increase cardiac output during
exercise. Sun et al. [8] analyzed CPET findings in PAH patients
with a mean cardiac index of 2.2 L/min/m2 and found a peak
VO2 of about 44%, slightly lower than the values we found in our
IPAH subjects. In our study, the peak VO2 was significantly higher
in Sch-PAH patients compared to IPAH patients, even when
expressed as mL/kg/min or a percent-predict value, which
minimizes any heterogeneity between the groups. Furthermore,
our subjects with IPAH had lower VO2 values at AT than our
Sch-PAH patients, indicating the earlier development of lactic
acidosis during exercise.
Moreover, the slope of VO2-WR, an index known to reflect
circulatory or peripheral dysfunction, has been used to evaluate
aerobic efficiency. This slope in IPAH patients was shallower than
in Sch-PAH patients, reflecting a higher dependence on anaerobic
metabolism during exercise in IPAH. [8,19].
We did not find differences in 6MWD between the groups.
Moreover, there were no correlations between 6MWD and
parameters of aerobic capacity assessed by CPET, even with
NYHA-FC. Although its importance in day practice, it is possible
that the submaximal nature of the test, with lesser cardiovascular
and ventilatory stress, had limited its capacity to detect disparities
between the groups when compared to CPET. [24,25].
Table 1. Baseline patient characteristics.
Sch-PAH IPAH p value




BMI, kg/m2 24.664 23.762 0.62




FVC, % 81.5613 91.8625 0.32
FEV1, % 78.4613 88.8622 0.29
FEV1/FVC 0.7960.1 0.8360.1 0.23
DLCO, % 63611 61610 0.72
PaCO2, mmHg 3363 3366 0.93
PaO2, mmHg 75610 78610 0.44
Six-minute-walk distance, m 474662 462678 0.40
Definition of Abbreviations: BMI, body mass index; NYHA, New York Heart
Association; FVC, forced vital capacity; FEV, forced expiratory volume; DLCO, carbon
monoxide diffusing capacity; PaCO2, arterial carbon dioxide partial pressure; PaO2,
arterial oxygen partial pressure.
doi:10.1371/journal.pone.0087699.t001
Table 2. Hemodynamic characteristics.
Parameter Sch-PAH IPAH p value
Mean pulmonary artery pressure, mmHg 57.5618.5 63.8617.1 0.47
Pulmonary capillary wedge pressure, mmHg 12.662.8 9.963.3 0.10
Right atrial pressure, mmHg 11.965 9.762 0.26
Pulmonary vascular resistance, IU 12.365.6 14.868.1 0.46
Cardiac output, L/min 4.0060.6 4.0961.2 0.84
Cardiac index, L/min/m2 2.3760.5 2.4960.7 0.69
Acute vasodilator response, n 0 0
doi:10.1371/journal.pone.0087699.t002
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Differences in Ventilatory Efficiency and Gas Exchange
PAH patients often have a ventilatory inefficiency, which is
defined as an abnormally high ventilatory response relative to CO2
output and expressed during CPET as either a ratio at the AT or a
slope obtained below the AT. This response has been related to
areas of high V/Q mismatching or increased alveolar ventilation
associated with several mechanisms, and is proportional to PAH
severity. [7,8,26] A VE-VCO2 slope greater than 48 is associated
with limited survival in PAH [13]. In our study, this slope was
above 48 in 55% of IPAH patients, however all Sch-PAH subjects
had this slope bellow this level. Moreover, this slope was
significantly steeper in IPAH subjects than in Sch-PAH subjects
(Table 3; Figure 1). Severe arterial hypoxemia and the develop-
ment of right-to-left shunting during exercise could be additional
explanations for the increases in DVE/DVCO2 [27] but they were
not present in our patients.
Excessive ventilation in PAH patients is often accompanied by a
reduction in PETCO2. In healthy subjects, a rise in PETCO2 is
expected between rest and the AT, with a subsequent reduction in
PETCO2 at maximal exercise. [8,28] In our study, there was a
trend toward lower PETCO2 values at AT in IPAH patients.
Moreover, there was a tendency for PETCO2 to rise between rest
and AT in Sch-PAH patients, contrasting with a progressive fall in
PETCO2 in IPAH subjects (Figure 2), suggesting more preserved
gas exchange function in Sch-PAH. Hansen et al. [29] emphasized
the exercise-induced decline in PETCO2 as a marker for PAH as
opposed to COPD and left ventricular failure. Furthermore,
Yasunobu et al. [28] showed that the exercise-induced fall in
PETCO2 that is observed in PAH is proportional to the severity of
the disease.
Figure 1. Contrasting exercise responses in two subjects with
similar resting hemodynamic impairment (CI 2.24 L/min/m2 for
Sch-PAH subject, and CI 2.21 L/min/m2 for IPAH patient). Upper
panel: the ratio of increase in VO2 to work rate (DVO2/DWR); middle
panel: slope of VE-VCO2; lower panel: increases in heart rate as a
function of VO2.
doi:10.1371/journal.pone.0087699.g001
Table 3. Cardiopulmonary exercise testing parameters.
Sch-PAH IPAH p value
WR, watts 84629 52617 0.006
Metabolic parameters
VO2 peak, % predicted 75.5621.4 54.0616.1 0.016
VO2 peak, mL/kg/
/min 17.565.3 12.663.2 0.016
VO2 at AT, % predicted 51.369.3 40.3613.0 0.040
DVO2/DWR, mL/min
/W 8.261.0 6.861.8 0.030
Ventilatory parameters
VT at AT, L 1.160.3 0.960.2 0.090
VE at AT, L/min 25.666.2 22.665.2 0.300
VE/MMV peak 0.6460.17 0.5360.17 0.220
VE/VO2 at AT 33.666.0 42.369.4 0.056
VE/VCO2 at AT 38.865.5 46.6610.8 0.055
DVE/DVCO2 40.363.9 55.6619.8 0.020
Cardiovascular parameters
HR at peak, % predicted 85.669.7 79.0610.0 0.200
O2 Pulse, % predicted 87.5620.9 65.5616.4 0.015
DHR/DVO2, beat/L
/min 80.1620.6 123.0639.2 0.020
Gas exchange parameters
PETCO2 at AT, mmHg 31.063.8 28.566.1 0.18
PETO2 at AT, mmHg 102.164.2 104.166.8 0.50
O2 sat at rest, % 9662 9661 0.64
O2 sat at peak exercise, % 9364 9464 0.58
Subjective parameters
Borg - Dyspnea at peak 762 662 0.52
Borg - Leg effort at peak 762 562 0.09
Definition of Abbreviations: WR, work rate; VO2, oxygen uptake; VE, minute
ventilation; AT, anaerobic threshold; VT, tidal volume; MMV, maximal minute
ventilation; VCO2, carbon dioxide uptake; HR, heart rate; PETCO2, end-expiratory
pressure for carbon dioxide; PETO2, end-expiratory pressure for oxygen; O2 sat,
oxyhemoglobin saturation by pulse oximetry.
doi:10.1371/journal.pone.0087699.t003
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Differences in Cardiovascular Responses to Exercise
O2 pulse (VO2/HR) is determined by stroke volume and O2
extraction. In our study, as there was an absence of severe
oxyhemoglobin desaturation, the higher peak O2 pulse seen in
Sch-PAH subjects probably reflects greater increases in stroke
volume during exercise compared to IPAH subjects. Likewise, the
inability to augment stroke volume during exercise leads to a
disproportional increase in heart rate as a function of the
metabolic demand (DHR/DVO2). This response was predomi-
nantly observed in our patients with IPAH, as opposed to Sch-
PAH (Table 3; Figure 2).
Correlations between Resting Hemodynamics and
Exercise Measurements
The resting cardiac index is known to correlate well with
functional limitation in IPAH. [10]. Accordingly, in our patients, a
correlation of resting CI to peak VO2 was observed in IPAH
subjects, but not in Sch-PAH. Also, we found a significant
correlation between peak VO2 and resting CI with ventilatory
(DVE/DVCO2) and aerobic efficiency (DVO2/DWR) only in
IPAH patients (Tables 4 and 5). Although no definite conclusions
can be made on the correlation values, this is additional evidence
of a more pronounced cardiovascular limitation in IPAH,
indicating that patients with Sch-PAH have a greater ability to
increase pulmonary blood flow during exercise, even with similar
resting pulmonary hemodynamics (Table 2). Moreover, these
finding supports the contention that selected CPET variables
should be used with caution when assessing the prognosis or
severity of patients with non-idiopathic PAH, as stated in a recent
study involving various etiologies of PAH. [30].
Study Limitations
There are some limitations in our study that need to be
acknowledged. The single-center nature of the study and our
location in an area of Brazil that is not endemic for schistosomiasis
Figure 2. The behavior of PETCO2 between rest and maximal exercise in Sch-PAH and IPAH subjects.
doi:10.1371/journal.pone.0087699.g002
Table 4. Correlation coefficients between resting CI and key
exercise variables obtained during CPET, NYHA-FC and 6MWT
in patients with Sch-PAH and IPAH.
Sch-PAH IPAH
NYHA-FC 20.85* 20.74*
6MWD, m 20.03 0.25




Definition of Abbreviations: NYHA-FC, New York Heart Association functional class;
VO2, oxygen uptake; WR, work rate; VE, minute ventilation; VCO2, carbon dioxide
uptake.
doi:10.1371/journal.pone.0087699.t004
Table 5. Correlation coefficients between VO2 peak (%
predicted) with: NYHA-FC, 6MWT and selected CPET variables
in patients with Sch-PAH and IPAH.
Sch-PAH IPAH
NYHA-FC 20.82** 20.83**





Definition of Abbreviations: NYHA-FC, New York Heart Association functional class;
VO2, oxygen uptake; WR, work rate; VE, minute ventilation; VCO2, carbon dioxide
uptake.
doi:10.1371/journal.pone.0087699.t005
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may account for some selection bias; however, this bias is
minimized by intern migratory practices to a cosmopolitan city
like Sa˜o Paulo. Also, as a result of restricted selection criteria, this
study included a small number of patients, which limit the
extrapolation of the results for different phenotypes of Sch-PAH
subjects; moreover, the probability of a type II error must be
considered in some comparisons between the groups. The female
preponderance in IPAH group might explain some differences
observed during CPET; however, the responses in percent-predict
(gender-adjusted) were consistent with those found in absolute
values, which minimizes this heterogeneity. Also, we were unable
to evaluate arterial blood gases in all subjects during exercise,
making it impossible to accurately assess the behavior of VD/VT.
In conclusion, patients with Sch-PAH had higher aerobic
capacity, lower submaximal ventilatory and cardiovascular stress-
es, and less impaired pulmonary gas exchange abnormalities than
IPAH subjects with similar resting hemodynamic dysfunction.
These findings suggest that the more benign clinical course of Sch-
PAH could be due to the less impaired ability of the right ventricle
to increase pulmonary blood flow during exercise, as compared to
IPAH subjects. This hypothesis deserves further investigation in
larger epidemiological studies.
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